The Access Committee examines broad trends related to Market Access and the Health Technology Assessments (HTA) in Japan. Its primary goal is to ensure that HTA guidelines are formulated and implemented in a manner that values innovation and promotes greater patient access. The Access Committee wishes to ensure that global best practices related to HTA are understood by policymakers and adopted in Japan. These best practices include a transparent HTA review process, a robust dialogue between industry and government, and a health care system that continues to encourage the rapid introduction of safe and effective medicines for patients. The Committee develops materials for external stakeholders and meets with policymakers to explain the EFPIA positions on HTA and other market access issues, including the 14 Day Rule.